AVEO Pharmaceuticals , Nasdaq: AVEO
Developing a renal cell carcinoma drug similar to blockbuster Avastin.
Industry: Health Care
First Day Return: -0.1%
Industry: Health Care
| IPO Data | |
|---|---|
| IPO File Date | 12/16/2009 |
| Offer Price | $9.00 |
| Price Range $13.00 - $15.00 | |
| Offer Shares (mm) | 9.0 |
| Deal Size ($mm) | $81 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 03/11/2010 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $81 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2001 |
| Employees at IPO | n/a |
| Website www.aveopharma.com | |
AVEO Pharmaceuticals (AVEO) Performance
